Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities
PS Mettu, MJ Allingham, SW Cousins - Progress in retinal and eye …, 2021 - Elsevier
Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the
treatment of neovascular age-related macular degeneration (NVAMD). However, many …
treatment of neovascular age-related macular degeneration (NVAMD). However, many …
Recent developments in age-related macular degeneration: a review
WM Al-Zamil, SA Yassin - Clinical interventions in aging, 2017 - Taylor & Francis
Background Visual impairment in elderly people is a considerable health problem that
significantly affects quality of life of millions worldwide. The magnitude of this issue is …
significantly affects quality of life of millions worldwide. The magnitude of this issue is …
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two …
Background Faricimab is a bispecific antibody that acts through dual inhibition of both
angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two …
angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two …
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
OBJECTIVE: Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of
Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular …
Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular …
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)
S Rofagha, RB Bhisitkul, DS Boyer, SVR Sadda… - Ophthalmology, 2013 - Elsevier
Purpose To assess long-term outcomes 7 to 8 years after initiation of intensive ranibizumab
therapy in exudative age-related macular degeneration (AMD) patients. Design Multicenter …
therapy in exudative age-related macular degeneration (AMD) patients. Design Multicenter …
[HTML][HTML] HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration
PU Dugel, RP Singh, A Koh, Y Ogura, G Weissgerber… - Ophthalmology, 2021 - Elsevier
Purpose To report the 96-week outcomes from HAWK and HARRIER. Design Phase 3,
prospective, randomized, double-masked, multicenter studies comparing efficacy and safety …
prospective, randomized, double-masked, multicenter studies comparing efficacy and safety …
Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular …
MG Maguire, DF Martin, G Ying, GJ Jaffe, E Daniel… - Ophthalmology, 2016 - Elsevier
Purpose To describe outcomes 5 years after initiating treatment with bevacizumab or
ranibizumab for neovascular age-related macular degeneration (AMD). Design Cohort …
ranibizumab for neovascular age-related macular degeneration (AMD). Design Cohort …
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six–week results of the VIEW studies
Purpose To determine efficacy and safety of intravitreal aflibercept in patients with
neovascular age-related macular degeneration (AMD) during a second year of variable …
neovascular age-related macular degeneration (AMD) during a second year of variable …
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Age-related macular degeneration (AMD) is still referred to as the leading cause of severe
and irreversible visual loss world-wide. The disease has a profound effect on quality of life of …
and irreversible visual loss world-wide. The disease has a profound effect on quality of life of …
[HTML][HTML] Macular atrophy in the HARBOR study for neovascular age-related macular degeneration
SVR Sadda, LL Tuomi, B Ding, AE Fung, JJ Hopkins - Ophthalmology, 2018 - Elsevier
Purpose To evaluate macular atrophy (MA) presence in the 24-month HARBOR study
(NCT00891735) for neovascular age-related macular degeneration (AMD). Design Post hoc …
(NCT00891735) for neovascular age-related macular degeneration (AMD). Design Post hoc …